Figure 3
Figure 3. Predictive value of the miRNA signature for aGVHD. (A) The expression of miR-423, miR-199a-3p, miR-93*, miR-377, miR-155, and miR-30a in the plasma of aGVHD patients prior to aGVHD diagnosis (median = 16 days before diagnosis). (B) ROC curve of the 4-miRNA panel (miR-423, miR-199a-3p, miR-93*, miR-377) 6 weeks after HCT for prediction of aGVHD before onset. (C) Plasma concentration of sIL-2Rα 6 weeks after HCT in non-GVHD and aGVHD patients before aGVHD diagnosis. (D) The expression of the 4-miRNA panel 2 weeks after HCT in plasma of aGVHD and non-GVHD patients. (E) ROC curve of the 4-miRNA panel 2 weeks after HCT. (F) Plasma concentration of sIL-2Rα 2 weeks after HCT. (G) ROC curve of sIL-2Rα 2 weeks after HCT.

Predictive value of the miRNA signature for aGVHD. (A) The expression of miR-423, miR-199a-3p, miR-93*, miR-377, miR-155, and miR-30a in the plasma of aGVHD patients prior to aGVHD diagnosis (median = 16 days before diagnosis). (B) ROC curve of the 4-miRNA panel (miR-423, miR-199a-3p, miR-93*, miR-377) 6 weeks after HCT for prediction of aGVHD before onset. (C) Plasma concentration of sIL-2Rα 6 weeks after HCT in non-GVHD and aGVHD patients before aGVHD diagnosis. (D) The expression of the 4-miRNA panel 2 weeks after HCT in plasma of aGVHD and non-GVHD patients. (E) ROC curve of the 4-miRNA panel 2 weeks after HCT. (F) Plasma concentration of sIL-2Rα 2 weeks after HCT. (G) ROC curve of sIL-2Rα 2 weeks after HCT.

Close Modal

or Create an Account

Close Modal
Close Modal